RxDoctor Payments Data

Danielle Belser, MD

Hospice and Palliative Medicine · Middletown, NYNPI 1497066187

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $158 of the $178 with a category attached, or 88.8%. It is spread thinly across 9 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.

$178in general payments, 2019–2025

Across 10 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$36
  • Axsome Therapeutics, Inc.$23
  • Bayer$21
  • CSL Behring$20
  • Merck$19
  • Novo Nordisk$17
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$15889%
  • Education$2011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$178 in reported general payments places this provider in the 55th percentile of 133 hospice and palliative medicine providers in New York.

See all hospice and palliative medicine providers in New York

Medicare billing

Part B allowed, 2024
$92,706
Medicare patients
361
Services billed
2,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin29$1,211
Azithromycin76$364
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav34$253
Nystatin11$230
Methylprednisolone30$223
Doxycycline Hyclate19$215
Fluticasone Propionate16$177
Hydrocortisone27$121
Mupirocin15$121
Ondansetron OdtOndansetron11$114
Prednisone71$109
Fluconazole11$60
Naproxen23$58
Methocarbamol12$16
PaxlovidNirmatrelvir/Ritonavir14$0

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPaxlovid$13$014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 133 hospice and palliative medicine providers in New York.

Other hospice and palliative medicine in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →